Thermo Fisher Scientific has introduced a new version of its Vanquish Charged Aerosol Detector (CAD), designed to improve sensitivity and broaden application scope in pharmaceutical analysis — particularly for compounds without chromophores.

The updated Vanquish CAD P Series is aimed at enhancing workflows in drug safety testing and the development of novel therapeutic modalities. According to the company, the system supports regulatory-compliant workflows while delivering more accurate quantification across a wider range of analytes.

Key improvements include application-dependent sensitivity gains over the previous model, and a new temperature coupling mode intended to support detection of semi-volatile compounds. This feature is expected to provide users with a more complete profile of sample components.

Professor Jim Grinias, Ph.D., of the Department of Chemistry & Biochemistry at Rowan University, commented: “As an early adopter of the Charged Aerosol Detector, I am pleased with the reliability and advancements the technology provides us with for developing efficient HPLC methods that aim to enhance drug safety. My students really enjoy working with this technology, and we look forward to our next publication focused on results obtained using the new detector.”

Thermo Fisher says the system also simplifies onboarding and operation, making it easier for users in both academic and industrial labs to optimize processes for routine analysis.

“The new CAD offers higher sensitivity than previous versions and remains the obvious choice when deciding between other detection methods such as ELSD and RID for difficult-to-detect compounds,” said Nicky Burbidge, vice president and general manager of High Performance Chromatography Solutions at Thermo Fisher. “This universal detector launch supports our Mission to enable our customers make the world healthier, cleaner and safer.”